$MED
MEDIFAST INC

2023 Q2 Form 10-Q Financial Statement

#000162828023014622 Filed on May 01, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $296.2M $349.0M $417.6M
YoY Change -34.66% -16.43% 22.58%
Cost Of Revenue $85.47M $102.6M $115.3M
YoY Change -35.08% -11.03% 25.18%
Gross Profit $210.7M $246.4M $302.3M
YoY Change -34.5% -18.49% 21.62%
Gross Profit Margin 71.14% 70.6% 72.39%
Selling, General & Admin $172.0M $192.9M $247.2M
YoY Change -36.93% -21.97% 26.28%
% of Gross Profit 81.63% 78.28% 81.78%
Research & Development $1.100M $1.000M $900.0K
YoY Change -8.33% 11.11% -10.0%
% of Gross Profit 0.52% 0.41% 0.3%
Depreciation & Amortization $3.368M $2.974M $2.444M
YoY Change 23.28% 21.69% 117.44%
% of Gross Profit 1.6% 1.21% 0.81%
Operating Expenses $172.0M $192.9M $247.2M
YoY Change -36.93% -21.97% 26.28%
Operating Profit $38.71M $53.51M $55.09M
YoY Change -20.95% -2.86% 4.33%
Interest Expense $462.0K -$181.0K -$95.00K
YoY Change -381.71% 90.53% -513.04%
% of Operating Profit 1.19% -0.34% -0.17%
Other Income/Expense, Net $411.0K -$182.0K -$111.0K
YoY Change -344.64% 63.96% -364.29%
Pretax Income $39.12M $53.33M $54.98M
YoY Change -19.84% -3.0% 4.04%
Income Tax $8.837M $13.36M $13.20M
% Of Pretax Income 22.59% 25.05% 24.0%
Net Earnings $30.28M $39.97M $41.78M
YoY Change -22.58% -4.34% 1.75%
Net Earnings / Revenue 10.22% 11.45% 10.01%
Basic Earnings Per Share $2.78 $3.68 $3.62
Diluted Earnings Per Share $2.77 $3.67 $3.59
COMMON SHARES
Basic Shares Outstanding 10.89M shares 10.84M shares 11.56M shares
Diluted Shares Outstanding 10.92M shares 10.90M shares 11.64M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $147.4M $123.7M $240.1M
YoY Change 20.69% -48.45% -42.7%
Cash & Equivalents $147.4M $123.7M $118.0M
Short-Term Investments $122.1M
Other Short-Term Assets $12.52M $9.674M $13.23M
YoY Change -25.1% -26.86% 100.41%
Inventory $68.90M $96.90M $189.0M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $228.8M $230.3M $324.3M
YoY Change -5.95% -28.97% 15.04%
LONG-TERM ASSETS
Property, Plant & Equipment $54.41M $55.96M $57.80M
YoY Change -7.06% -3.19% 85.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $14.27M $13.71M $12.03M
YoY Change 10.14% 13.99% 286.44%
Total Long-Term Assets $89.91M $91.29M $97.18M
YoY Change -7.55% -6.06% 118.21%
TOTAL ASSETS
Total Short-Term Assets $228.8M $230.3M $324.3M
Total Long-Term Assets $89.91M $91.29M $97.18M
Total Assets $318.7M $321.6M $421.4M
YoY Change -6.41% -23.69% 29.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $105.2M $113.3M $174.4M
YoY Change -32.04% -35.02% 23.4%
Accrued Expenses $5.405M $5.411M $6.663M
YoY Change -15.26% -18.79% 80.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $114.9M $131.7M $181.0M
YoY Change -38.94% -27.23% 24.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $18.27M $18.96M $24.38M
YoY Change -20.27% -22.21% 269.38%
Total Long-Term Liabilities $18.27M $18.96M $24.38M
YoY Change -20.27% -22.21% 269.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $114.9M $131.7M $181.0M
Total Long-Term Liabilities $18.27M $18.96M $24.38M
Total Liabilities $133.2M $150.7M $205.4M
YoY Change -36.91% -26.63% 35.58%
SHAREHOLDERS EQUITY
Retained Earnings $163.9M $151.8M $203.1M
YoY Change 26.85% -25.23% 13.71%
Common Stock $11.00K $11.00K $12.00K
YoY Change 0.0% -8.33% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $185.6M $170.9M $216.0M
YoY Change
Total Liabilities & Shareholders Equity $318.7M $321.6M $421.4M
YoY Change -6.41% -23.69% 29.12%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $30.28M $39.97M $41.78M
YoY Change -22.58% -4.34% 1.75%
Depreciation, Depletion And Amortization $3.368M $2.974M $2.444M
YoY Change 23.28% 21.69% 117.44%
Cash From Operating Activities $43.15M $64.06M $43.67M
YoY Change -1.41% 46.68% -33.15%
INVESTING ACTIVITIES
Capital Expenditures $1.744M $2.115M $3.009M
YoY Change -161.41% -29.71% -34.56%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $1.245M
YoY Change -100.0% -100.0% -66.35%
Cash From Investing Activities -$1.744M -$2.115M -$1.764M
YoY Change -247.55% 19.9% 100.91%
FINANCING ACTIVITIES
Cash Dividend Paid $19.16M $16.66M
YoY Change 15.02% 24.4%
Common Stock Issuance & Retirement, Net $10.00M
YoY Change 33.33%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -17.84M -$25.90M -$28.12M
YoY Change -82.52% -7.91% 26.56%
NET CHANGE
Cash From Operating Activities 43.15M $64.06M $43.67M
Cash From Investing Activities -1.744M -$2.115M -$1.764M
Cash From Financing Activities -17.84M -$25.90M -$28.12M
Net Change In Cash 23.57M $36.06M $13.82M
YoY Change -141.29% 160.9% -67.33%
FREE CASH FLOW
Cash From Operating Activities $43.15M $64.06M $43.67M
Capital Expenditures $1.744M $2.115M $3.009M
Free Cash Flow $41.40M $61.94M $40.66M
YoY Change -11.16% 52.33% -33.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000910329
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-31573
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Medifast, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3714405
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
100 International Drive
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Baltimore
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
21202
CY2023Q1 dei City Area Code
CityAreaCode
410
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
581-8042
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
MED
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10887193 shares
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
348983000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
417600000 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
102593000 usd
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
115314000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
246390000 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
302286000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
192879000 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
247199000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
53511000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
55087000 usd
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-181000 usd
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-95000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-16000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-182000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-111000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
53329000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
54976000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13361000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13195000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
39968000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
41781000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.68
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.62
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.67
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.59
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10864000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11557000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10899000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11638000 shares
CY2023Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.65
CY2022Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.64
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
39968000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
41781000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
9000 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
30000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-14000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
16000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
39977000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
41797000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
123748000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87691000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
96896000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
118856000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9674000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16237000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
230318000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
222784000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
55960000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57185000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17091000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18460000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13709000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12456000 usd
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
4528000 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
5328000 usd
CY2023Q1 us-gaap Assets
Assets
321606000 usd
CY2022Q4 us-gaap Assets
Assets
316213000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
113300000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
134690000 usd
CY2023Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
13031000 usd
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
428000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5411000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5776000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
131742000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
140894000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18964000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20275000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
150706000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
161169000 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10887000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10928000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10887000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10873000 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
11000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
11000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
19030000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
21555000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
33000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
24000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
151826000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
139852000 usd
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
54000 shares
CY2023Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
0 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
6398000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
170900000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
155044000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
321606000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
316213000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
39968000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
41781000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2974000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2444000 usd
CY2023Q1 med Operating Lease Expense Non Cash
OperatingLeaseExpenseNonCash
1369000 usd
CY2022Q1 med Operating Lease Expense Non Cash
OperatingLeaseExpenseNonCash
1619000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
606000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2275000 usd
CY2023Q1 us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
0 usd
CY2022Q1 us-gaap Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
11000 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
800000 usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-21960000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8929000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6563000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3107000 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
887000 usd
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6632000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-21897000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6084000 usd
CY2023Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-12603000 usd
CY2022Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-14081000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
64059000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
43673000 usd
CY2023Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0 usd
CY2022Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
1245000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2115000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3009000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2115000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1764000 usd
CY2023Q1 med Proceeds From Stock Options Exercised Directors
ProceedsFromStockOptionsExercisedDirectors
105000 usd
CY2022Q1 med Proceeds From Stock Options Exercised Directors
ProceedsFromStockOptionsExercisedDirectors
0 usd
CY2023Q1 us-gaap Payments For Repurchase Of Other Equity
PaymentsForRepurchaseOfOtherEquity
3236000 usd
CY2022Q1 us-gaap Payments For Repurchase Of Other Equity
PaymentsForRepurchaseOfOtherEquity
1459000 usd
CY2023Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
19163000 usd
CY2022Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
16660000 usd
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3602000 usd
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
10000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-25896000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-28119000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9000 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
36057000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13820000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87691000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104183000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
123748000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
118003000 usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-46000 usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
62000 usd
CY2023Q1 us-gaap Dividends Cash
DividendsCash
18653000 usd
CY2022Q1 us-gaap Dividends Cash
DividendsCash
19663000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
155044000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
39968000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
606000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
105000 usd
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
3236000 usd
CY2023Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
3602000 usd
CY2023Q1 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9000 usd
CY2023Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
17994000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
170900000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
202474000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
41781000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
2275000 usd
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1459000 usd
CY2022Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
10000000 usd
CY2022Q1 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
0 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
16000 usd
CY2022Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
19063000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
216024000 usd
CY2023Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain amounts reported for prior periods have been reclassified to be consistent with the current period presentation. No reclassification in the condensed consolidated financial statements had a material impact on the presentation.</span>
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span>
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
12932000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
12670000 usd
CY2023Q1 us-gaap Retail Related Inventory Packaging And Other Supplies
RetailRelatedInventoryPackagingAndOtherSupplies
4296000 usd
CY2022Q4 us-gaap Retail Related Inventory Packaging And Other Supplies
RetailRelatedInventoryPackagingAndOtherSupplies
3611000 usd
CY2023Q1 med Inventory Non Food Finished Goods
InventoryNonFoodFinishedGoods
7032000 usd
CY2022Q4 med Inventory Non Food Finished Goods
InventoryNonFoodFinishedGoods
8738000 usd
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
78825000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
97675000 usd
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
6189000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3838000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
96896000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
118856000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
39968000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
41781000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10864000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11557000 shares
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
35000 shares
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
81000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10899000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11638000 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.68
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.62
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.67
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.59
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
26.52
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
66.68
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
33000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
54.98
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
32000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
54.98
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
4000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
27.18
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
29000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
58.65
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
32000 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
54.98
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
29000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
58.65
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
28000 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
52.76
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y3M18D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y3M18D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1300000 usd
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1300000 usd
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000 usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000 usd
CY2023Q1 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
225000 shares
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
606000 usd
CY2022Q1 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
152000 shares
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2275000 usd
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000 usd
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1800000 usd
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1804000 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1756000 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
103000 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0200
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4440000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5693000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5825000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4160000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2553000 usd
CY2023Q1 med Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
2858000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
25529000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1154000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
24375000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
33000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
24000 usd

Files In Submission

Name View Source Status
0001628280-23-014622-index-headers.html Edgar Link pending
0001628280-23-014622-index.html Edgar Link pending
0001628280-23-014622.txt Edgar Link pending
0001628280-23-014622-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
med-20230131xexx311.htm Edgar Link pending
med-20230131xexx312.htm Edgar Link pending
med-20230131xexx321.htm Edgar Link pending
med-20230331.htm Edgar Link pending
med-20230331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
med-20230331_lab.xml Edgar Link unprocessable
med-20230331_cal.xml Edgar Link unprocessable
med-20230331_def.xml Edgar Link unprocessable
med-20230331_pre.xml Edgar Link unprocessable
med-20230331_htm.xml Edgar Link completed